Van Meerbeeck J, Galdermans D, Bustin F, De Vos L, Lechat I, Abraham I
Thoracic Oncology, Ghent University Hospital, Gent, Belgium.
Eur J Cancer Care (Engl). 2014 May;23(3):370-9. doi: 10.1111/ecc.12146. Epub 2013 Oct 24.
Erlotinib has been shown to prolong progression-free (PFS) and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC). We report here on effectiveness data on the subsample of 261 patients from 40 centres in Belgium involved in the TRUST study. Median age was 63 years. Most (69.0%) were male and current/former smokers (84.7%); with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (74.3%), stage IV disease (75.1%) and adenocarcinoma by histology (54.0%). Erlotinib was administered mainly as second- (47.1%) or third-line treatment (48.3%). Response rate was 6.5%; disease control rate 58.3%. Median PFS was 2.2 months. Better PS (P = 0.0384), stage IIIB disease (P = 0.0018) and presence of rash (P < 0.0001) were associated with longer PFS. OS rates at 1, 2 and 3 years were 26.4%, 10.9% and 6.4% respectively. Median OS was 5.9 months. Female gender (P = 0.007), better PS (P < 0.0001), stage IIIB disease (P = 0.0355) and presence of rash (P < 0.0001) were associated with longer OS. The findings confirm the therapeutic benefit of erlotinib in a broad range of patients in a sample from a country with a historically high lung cancer morbidity and mortality burden. Several determinants of PFS and OS are identified.
厄洛替尼已被证明可延长晚期非小细胞肺癌（NSCLC）患者的无进展生存期（PFS）和总生存期（OS）。我们在此报告参与TRUST研究的来自比利时40个中心的261例患者子样本的有效性数据。中位年龄为63岁。大多数（69.0%）为男性且为当前/既往吸烟者（84.7%）；东部肿瘤协作组（ECOG）体能状态（PS）为0或1（74.3%），IV期疾病（75.1%），组织学类型为腺癌（54.0%）。厄洛替尼主要作为二线（47.1%）或三线治疗（48.3%）给药。缓解率为6.5%；疾病控制率为58.3%。中位PFS为2.2个月。较好的PS（P = 0.0384）、IIIB期疾病（P = 0.0018）和皮疹的出现（P < 0.0001）与更长的PFS相关。1年、2年和3年的OS率分别为26.4%、10.9%和6.4%。中位OS为5.9个月。女性（P = 0.007）、较好的PS（P < 0.0001）、IIIB期疾病（P = 0.0355）和皮疹的出现（P < 0.0001）与更长的OS相关。这些发现证实了在一个历史上肺癌发病率和死亡率负担较高的国家的样本中，厄洛替尼对广泛患者的治疗益处。确定了PFS和OS的几个决定因素。
